Related Experiment Video
Updated: Oct 3, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Tebentafusp for the treatment of metastatic uveal melanoma
Timo E Schank1,2, Jessica C Hassel1,2
1Department of Dermatology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Abstract:
Uveal melanoma is a rare disease; nevertheless, it is the most common primary intraocular malignancy among adults. Approximately half of affected patients will suffer from metastatic disease, mostly to the liver. No standard-of-care treatment exists for these patients. Median progression-free survival and overall survival for all types of treatment, including checkpoint inhibitors, have remained poor. However, the most recent phase III study results for tebentafusp, a member of a new-in-class molecule, are raising hopes for stage IV uveal melanoma patients. In this review, we examine the current literature, focusing on the most recent trial results for this new reagent. We evaluate the latest clinical results for tebentafusp and aim to shed light on its immunological strategy.
Insights
Tebentafusp offers new hope for uveal melanoma patients with stage IV disease. This novel therapy shows promise in improving survival outcomes for this rare and aggressive cancer.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Uveal melanoma is the most common primary intraocular malignancy in adults.
- Metastatic disease, primarily to the liver, affects approximately 50% of patients.
- Current treatments, including checkpoint inhibitors, offer limited survival benefits for metastatic uveal melanoma.
Purpose of the Study:
- To review the current literature on uveal melanoma treatments.
- To focus on recent clinical trial results for tebentafusp.
- To elucidate the immunological strategy of tebentafusp.
Main Methods:
- Literature review of current research on uveal melanoma.
- Analysis of phase III study results for tebentafusp.
- Evaluation of tebentafusp's mechanism of action.
Main Results:
- Tebentafusp, a novel molecule, has demonstrated promising results in recent phase III studies.
- The new therapy offers potential improvements for patients with stage IV uveal melanoma.
- Clinical data suggests a positive impact on progression-free and overall survival.
Conclusions:
- Tebentafusp represents a significant advancement in the treatment of metastatic uveal melanoma.
- The drug's unique immunological approach warrants further investigation.
- Hope is rising for patients with advanced-stage uveal melanoma due to tebentafusp's efficacy.
More Related Videos
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016